A clinical trial testing TG Therapeutics‘ CD20 inhibitor Briumvi (ublituximab-xiiy) in children with relapsing forms of multiple sclerosis (MS) will begin enrolling participants within the next few months, the developer announced, also unveiling details of the study’s design. The upcoming Phase 2/3 trial (NCT07220252) will run…
Discussion
It took exactly 14 days for my health insurance to pick the first fight with me this year. The letter arrived quietly, the way these things always do. Denied. Out of network. This time it was Octave Bioscience’s Multiple Sclerosis Disease Activity (MSDA) test, a blood test that evaluates…
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis (MS), including acute and chronic inflammation, as well as Epstein-Barr virus (EBV) reactivation, according to new trial data. The Phase 2 CALLIPER trial (NCT05054140)Â investigated vidofludimus calcium against a…
Discussion
Like many of my peers in the military, I developed the ability to fall asleep in any position or place and at any time that I wasn’t actively engaged in something. On one occasion, during a particularly loud and turbulent flight, I managed to stay awake just long enough to…
People with multiple sclerosis (MS) who engage in more physical activity tend to have less severe physical and cognitive disability, a study demonstrated. While past exercise levels showed no correlation with later disease onset or slower disability accumulation, current exercise habits were significantly associated with physical disability in MS…
Get regular updates to your inbox.
